<< Read Full Article
<< Read Full Article
HealthShares Emerging Cancer (HHJ Quote) was Thursday's best performer among exchange-traded funds, as positive headlines out of holding Dendreon (DNDN Quote) boosted the ETF by more than 4%.
Dendreon jumped 43% after the biotech company said the Food and Drug Administration provided confirmation it will accept either a positive interim or final analysis of survival in order to approve the prostate cancer vaccine, Provenge.
The HealthShares Emerging Cancer ETF was recently up 96 cents, or 4.1%, to $24.49. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,471.58 | 1,108.86 | 2,175.81 | 32.75 |
Oil *
79.69
|
|
UP
126.74
|
UP
13.23
|
UP
31.21
|
UP
0.74
|
10 Yr
3.28%
SPDR Gold
117.38
|
|
+1.23%
|
+1.21%
|
+1.46%
|
+2.31%
|
Data delayed 20 minutes |
Connect with TheStreet